Generic Aciphex Sprinkle
At this time, Aciphex Sprinkle (rabeprazole sprinkle) capsules are available in brand-name form only. A generic version of the drug is not expected to become available until after the exclusivity rights expire, which is not until September 2016. Unless there are lawsuits or new patents filed, companies may begin making generic Aciphex Sprinkle products after the exclusivity rights expire.
Aciphex® Sprinkle™ (rabeprazole sprinkle) is a prescription medication approved for treating gastroesophageal reflux disease (GERD) in children age 1 to 11 years old. It belongs to a group of medications known as proton pump inhibitors, or simply PPIs.
Aciphex Sprinkle is made by Eisai, Inc., and marketed by Janssen Pharmaceuticals, Inc. Currently, the drug is protected by exclusivity rights that prevent any generic versions from being sold in the United States.
Eisai holds the exclusive rights to market Aciphex Sprinkle in the United States until September 2016. This is the earliest predictable date that a generic version of the drug could become available.
However, this could change, depending on many factors, such as lawsuits or patents for new Aciphex Sprinkle uses. Once the medication is no longer protected by exclusivity rights, there may be several companies that will manufacture a generic Aciphex Sprinkle drug.
No -- rabeprazole is the active ingredient in Aciphex Sprinkle, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.